

**Novartis Office of Grants & Education
Request for Proposal (RFP) - Professional Medical Education**

The Novartis Office of Grants & Education (NOGE) supports independent high-quality medical educational programs which provide fair-balanced, evidence-based, current scientific information to healthcare professionals in order to improve patient care. Activities should have an educational focus, be independent of commercial bias and be non-promotional in nature. NOGE will perform these duties in compliance with laws, regulations and guidelines as established by the ACCME, PhRMA Code, OIG, other regulatory agencies and in compliance with Novartis guidelines and policies.

| | |
|-----------------------------|--|
| Key Dates: | RFP Issued: June 1, 2026 Applications Due to Novartis: July 31, 2026 by 5 PM EST Notification of Grant Decisions: Sept. – Oct. 2026 Educational Programming Starts: Q4 2026 – Q1 2027 |
| Therapeutic Area: | Gastroenteropancreatic Neuroendocrine Tumors (GEP NET) |
| Educational Need: | Neuroendocrine tumors (NETs) are a diverse group of cancers that develop from the diffuse neuroendocrine system. They most commonly arise in the gastroenteropancreatic (GEP) tract and the bronchopulmonary system, and their incidence has risen steadily over the past 30 years. Because GEP NETs are complex and heterogeneous, patients should be managed by a multidisciplinary team that may include surgeons, pathologists, medical oncologists, radiologists, interventional radiologists, nuclear medicine physicians, radiation oncologists, and nurses, all of whom should stay up to date on advances in the field. While surgery remains the main treatment for localized disease, systemic therapies for metastatic NETs have expanded significantly in recent years. The rising incidence of these tumors, their relative rarity compared with other cancers, and the growing number of newer treatment options highlight the importance of ongoing medical education to support clinicians in selecting the most appropriate care for their patients. |
| Geographic Scope: | Primary geography of interest: United States (National, Regional, and/or Local) Note: Applications for this RFP must be US-focused for the audience, expert faculty, educational needs, and standards of care. |
| Project Description: | NOGE has identified the need for innovative continuing medical education programs that strive to optimize patient outcomes through education on: <ul style="list-style-type: none"> • Recognize the challenges with the accurate diagnosis and management of NETs/Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) • Educate on the relevance of precision medicine in the accurate diagnosis and management of NETs/GEP-NETs, especially in the community setting • Understand the impact of NETs/GEP-NETs on patient quality of life (QOL) • Understand evolving data regarding diagnosis and imaging modalities for NETs/GEP-NETs • Recognize the importance of early intervention upon clinical or radiological progression of NETs/GEP-NETs • Explain the importance of appropriate treatment sequencing and selection for NETs/GEP-NETs |

| | |
|---|--|
| | <ul style="list-style-type: none"> • Discuss the current and emerging treatment landscape for NETs/GEP-NETs • Consider the appropriate patient type and tumor origin/characteristics when determining individual treatment selections • Consider the use of guidelines for the diagnosis and treatment of NETs/GEP-NETs • Apply a multidisciplinary approach to the management of NETs/GEP-NETs <p>NOGE is seeking to support innovative and engaging programs including, but not limited to, the following:</p> <ul style="list-style-type: none"> • National Society Conferences • Curriculum-based education including both live and web-based formats • Programs with novel opportunities for audience engagement • Event series with regional and/or national impact <p>Note: Program placement is independent of Novartis. Program placement should reflect appropriate reach efforts.</p> |
| <p>Target Audience:</p> | <p>Healthcare providers who are involved in the care of patients with GEP NET: Community & Academic Oncologists, Radiation Oncologists; Nuclear Medicine Physicians; Diagnostic Radiologists; Interventional Radiologists; NP, PA, Nurses</p> <p>Educational providers should include target number of participants. Further, please include details on proposed audience recruitment.</p> <p>Please note: Novartis will not participate in the distribution of invitations to the CME/CE event.</p> |
| <p>Available Funding:</p> | <p>Multiple single-support or multi-support initiatives may be funded; up to \$350,000 in total support is available for RFP responses.</p> |
| <p>Submission Requirements:</p> | <p>If working with an Accredited Provider and/or Educational Partner, they should be listed in the Novartis grant application. Grant requests must be submitted by the Office of CME (if from an Academic Institution/Hospital) via the Novartis Grants Central Station website: www.ngcs.novartis.com by 5 PM EST on August 14, 2026 to be considered.</p> <p>The grant application should include “RFP Response” within the Program Title [example: “RFP Response: <i>Program Title</i>”].</p> <p>Proposals that include collaborations with third parties, including (but not limited to) community-based hospitals, medical societies, health education companies/centers, not-for-profit organizations, and academic institutions, are encouraged, as appropriate.</p> |
| <p style="text-align: center;">For grant request submission information, FAQs, and eligibility criteria, please visit: https://www.novartis.com/us-en/about/external-funding/educational-grants/professional-medical-education-grants</p> <p style="text-align: center;">If you have any questions regarding this RFP, you should only contact NOGE at Riaz.Baxamusa@novartis.com</p> | |

[Please title the subject of your email: "RFP NET"].

References

1. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. *CA Cancer J Clin*. 2018 Nov;68(6):471-487. doi: 10.3322/caac.21493. Epub 2018 Oct 8. PMID: 30295930.
2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol*. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320.
3. Strosberg JR, Al-Toubah T, El-Haddad G, Lagunes DR, Bodei L. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients. *J Nucl Med*. 2024 Jan 18;jnumed.123.265706. doi: 10.2967/jnumed.123.265706. Epub ahead of print. PMID: 38238038.